Karakike (ESCAPE), 2021 NCT04339712
tocilizumab vs. anakinra
COVID-19 severe or critically
TOCI-RAF Study Group (Campochiaro), 2020
tocilizumab vs. control
COVID-19 severe or critically
Somers, 2020
tocilizumab vs. control
COVID-19 severe or critically
Mathilde, 2020
tocilizumab vs. control
COVID-19 severe or critically
Andrew, 2020
tocilizumab vs. control
COVID-19 severe or critically
Biran, 2020
tocilizumab vs. control
COVID-19 severe or critically
Klopfenstein, 2020
tocilizumab vs. control
COVID-19 severe or critically
Rashad, 2021 NCT04519385
tocilizumab vs. dexamethasone
COVID-19 severe or critically
COVACTA (Rosas), 2020 NCT04320615
tocilizumab vs. placebo
COVID-19 severe or critically
NCT04377750 (HMO-0224-20), 0 NCT04377750
tocilizumab vs. placebo
COVID-19 severe or critically
Rosas (REMDACTA), 2021 NCT04409262
tocilizumab vs. placebo
COVID-19 severe or critically
CORON-ACT, 0 NCT04335071
tocilizumab vs. placebo
COVID-19 severe or critically
Sarhan, 2022 NCT04779047
tocilizumab vs. remdesivir
COVID-19 severe or critically
Karampitsakos, 2021
tocilizumab vs. standard of care
COVID-19 severe or critically
Rojas-Marte, 2020
tocilizumab vs. standard of care
COVID-19 severe or critically
Pereira, 2020
tocilizumab vs. standard of care
COVID-19 severe or critically
CORIMUNO-TOCI-ICU (Group 2), 2020 NCT04331808
tocilizumab vs. standard of care
COVID-19 severe or critically
CORIMUNO-TOCI-1 (Group 1), 2020 NCT04331808
tocilizumab vs. standard of care
COVID-19 severe or critically
REMAP-CAP (tocilizumab), 2021 NCT02735707
tocilizumab vs. standard of care
COVID-19 severe or critically
Veiga, 2021 NCT04403685
tocilizumab vs. standard of care
COVID-19 severe or critically
ChiCTR2000030580, 0 ChiCTR2000030580
tocilizumab vs. standard of care
COVID-19 severe or critically
Talaschian, 2021 IRCT20081027001411N4
tocilizumab vs. standard of care
COVID-19 severe or critically
Hamed, 2021
tocilizumab vs. standard of care
COVID-19 severe or critically
MARIPOSA, 2021 NCT04363736
tocilizumab vs. tocilizumab
COVID-19 severe or critically
Belhassen-Garc??a, 2021
tocilizumab vs. tocilizumab
COVID-19 severe or critically
Sarhan, 2022 NCT04779047
tocilizumab vs. tocilizumab
COVID-19 severe or critically